Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Public ClinicalTrials.gov record NCT02748564. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and tolerability of IL-2 when given in combination with pembrolizumab to patients with advanced melanoma. Aldesleukin may stimulate white blood cells to melanoma cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving aldesleukin and pembrolizumab may kill more tumor cells. There are two parts to this study: * Phase Ib: To determine the safety and side effects of increasing doses of IL-2 in combination with pembrolizumab * Phase II: Once the maximum tolerated dose of IL-2 is determined, additional patients will be treated to determine if it is effective against the cancer.
Study identification
- NCT ID
- NCT02748564
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 10 participants
Conditions and interventions
Conditions
- Metastatic Melanoma
- Stage III Mucosal Melanoma of the Head and Neck
- Stage IIIA Skin Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Skin Melanoma
- Stage IVA Mucosal Melanoma of the Head and Neck
- Stage IVB Mucosal Melanoma of the Head and Neck
- Stage IVC Mucosal Melanoma of the Head and Neck
Interventions
- Aldesleukin Biological
- Laboratory Biomarker Analysis Other
- Pembrolizumab Biological
Biological · Other
Eligibility (public fields only)
- Age range
- 15 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2017
- Primary completion
- Oct 17, 2018
- Completion
- Jun 4, 2023
- Last update posted
- Aug 2, 2023
2017 – 2023
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cardinal Bernardin Cancer Center | Maywood | Illinois | 60153 | — |
| Indiana University | Bloomington | Indiana | 46996 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02748564, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02748564 live on ClinicalTrials.gov.